**Core Concept**
Testosterone therapy in men can lead to various physiological changes due to its anabolic and androgenic effects. This question tests the understanding of the long-term consequences of testosterone replacement therapy (TRT) in males.

**Why the Correct Answer is Right**
Prolonged testosterone treatment in men can lead to a condition known as **testosterone-induced hypogonadism** or **secondary hypogonadism**. This occurs due to negative feedback inhibition of the hypothalamic-pituitary-gonadal axis, resulting in decreased production of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) from the pituitary gland. Consequently, the testes receive less stimulation to produce testosterone, leading to a decrease in endogenous testosterone production.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the consequences of prolonged testosterone treatment.
**Option B:** While testosterone therapy can increase red blood cell mass, it does not directly cause polycythemia vera.
**Option C:** This option is not a known consequence of prolonged testosterone treatment.

**Clinical Pearl / High-Yield Fact**
To avoid testosterone-induced hypogonadism, it is essential to monitor testosterone levels and adjust the dosage as needed in men undergoing TRT. A common approach is to use a **testosterone level** of 400-800 ng/dL as a target range to minimize the risk of hypogonadism.

**Correct Answer:** D. Testosterone-induced hypogonadism (Secondary hypogonadism)